Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Analysts Love These Two Dividend Aristocrats but How Does the Smart Money Feel about Them?

Page 1 of 2

McDonald’s Corporation (NYSE:MCDand Johnson & Johnson (NYSE:JNJ) are each up more than 1.4% in early morning trade on the back of analyst upgrades. Analysts at Credit Suisse have upgraded McDonald’s Corporation (NYSE:MCD) to ‘Outperform’ from ‘Neutral’, and bumped up their target price to $112 from $100, while analysts at Deutsche Bank upgraded Johnson & Johnson (NYSE:JNJ) to ‘Buy’ from ‘Hold’ and assigned a price target of $110 per share. In this article, we will take a closer look at the upgraded stocks and see if the smart money sees the same potential in them as the analysts do.

McDonald's Corporation (NYSE:MCD)

We mention the hedge fund activity concerning McDonald’s and Johnson & Johnson because our research has shown that historically hedge funds’ stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about 6.0 basis points per month between 1999 and 2012; however the 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points during the same period. This means investors would have generated 10 percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas. We have been tracking the performance of these stocks since the end of August 2012 in real time and these stocks beat the market by 60 percentage points (118% return vs. the S&P 500’s 57.6% gain) over the last 36 months (see the details here).

Follow Mcdonalds Corp (NYSE:MCD)
Trade (NYSE:MCD) Now!

Analysts at Credit Suisse upgraded McDonald’s Corporation (NYSE:MCD) citing stronger same-store sales trends. McDonald’s stock has lagged its peers in recent years as its same-store sales have stalled. The analysts at Credit Suisse believe the chain’s third quarter sales will be positive and reverse the negative sentiment around the stock. Overall, eight analysts have ‘Buy’ ratings, nine have ‘Hold’ ratings, and one has a ‘Sell’ rating on the leading restaurant chain.

Like analysts, hedge funds are bullish on McDonald’s Corporation (NYSE:MCD). According to our data, 81 hedge funds owned $6.28 billion worth of the company’s stock (representing 6.90% of the float) on June 30, versus 89 funds and $6.83 billion respectively at the end of March. Among them, Southeastern Asset Management, which pruned its stake by 10% to 9.87 million shares was the top shareholder, followed by Jonathon Jacobson’s Highfields Capital Management, which kept its position unchanged at 9.8 million shares. On the other hand, s. Zach Schreiber’s Point Sate Capital established a new position of 4.55 million shares while Israel Englander’s Millennium Management increased its stake by 34% on the quarter to 2.74 million shares.

Follow Johnson & Johnson (NYSE:JNJ)
Trade (NYSE:JNJ) Now!

Analysts at Deutsche Bank upgraded Johnson & Johnson (NYSE:JNJ) after meeting with the company’s management. The analysts came away more confident on Johnson & Johnson’s growth prospects and believe the company has plenty of liquidity to pursue accretive mergers and acquisitions that unlock value for shareholders. Although Johnson & Johnson has a large drug portfolio, its stock has been relatively unscathed from the recent biotech sell off. Six analysts have ‘Buy’ ratings, eight have ‘Hold’ ratings, and one has a ‘Sell’ rating on the healthcare giant, with a consensus price target of $107.58 between them.

Hedge funds are bullish on Johnson & Johnson (NYSE:JNJ). A total of 78 hedge funds owned $4.38 billion of the company’s stock (representing 1.60% of the float) at the end of the second quarter, versus 77 funds and $4.58 billion respectively on March 31. Ken Fisher‘s Fisher Asset Management increased its position by 2% to 10.64 million shares, followed by Donald Yacktman’s Yacktman Asset Management, which trimmed its exposure by 12% to 7.44 million shares. Moreover, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital added 1.27 million shares to its stake, taking it to 1.31 million shares reported as of the end of June.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!